Functional Lung Avoidance for Individualized Radiation Therapy (FLAIR): A Randomized, Double-Blind Clinical Trial
Concurrent chemoradiotherapy is the standard treatment for locally advanced, unresectable
non-small cell lung cancer, but carries a risk of radiation pneumonitis of approximately
30%, and is associated with a decline in pulmonary quality of life.
Standard radiation planning aims to optimize dose to the anatomic lung volume, without
consideration of the differences in regional lung function. Functional lung avoidance
radiation therapy aims to reduce radiation therapy dose to regions of functioning lung, instead
depositing dose in areas of lung that are not well-ventilated. Functional lung regions are
determined using noble-gas MRI and co-registered to the radiation therapy planning CT scans.
Functional lung avoidance radiation therapy has been demonstrated to be feasible, and this trial
aims to compare outcomes between standard radiation therapy (with concurrent chemotherapy) vs.
functional lung avoidance radiation therapy (with concurrent chemotherapy).
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society